Abstract
Diabetes is an important risk factor for cardiovascular disease. However, clinical data suggests intensive glycemic control significantly increase rather than decrease cardiovascular mortality, which is largely due to the fact that a majority of oral anti-diabetic drugs have adverse cardiovascular effect. There are several large-scale clinical trials evaluating the cardiovascular safety of DPP4 inhibitors, a novel class of oral anti-diabetic medications, which have been recently completed. They were proven to be safe with regard to cardiovascular outcomes. However, concerns on the safety of heart failure have been raised as the SAVOR-TIMI 53 trial reported a 27% increase in the risk for heart failure hospitalization in diabetic patients treated with DPP4 inhibitor saxagliptin. In this review, we will discuss recent advances in the heart failure effects of DPP4 inhibition and GLP-1 agonism.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 299-304 |
| Number of pages | 6 |
| Journal | Heart Failure Reviews |
| Volume | 22 |
| Issue number | 3 |
| DOIs | |
| State | Published - May 1 2017 |
| Externally published | Yes |
Fingerprint
Keywords
- Cardiovascular outcomes
- DPP4
- Heart failure
- Incretin
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
DPP4 inhibitors and cardiovascular outcomes : safety on heart failure. / Xia, Chang; Goud, Aditya; D’Souza, Jason; Dahagam, Chanukya H.; Rao, Xiaoquan; Rajagopalan, Sanjay; Zhong, Jixin.
In: Heart Failure Reviews, Vol. 22, No. 3, 01.05.2017, p. 299-304.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - DPP4 inhibitors and cardiovascular outcomes
T2 - safety on heart failure
AU - Xia, Chang
AU - Goud, Aditya
AU - D’Souza, Jason
AU - Dahagam, Chanukya H.
AU - Rao, Xiaoquan
AU - Rajagopalan, Sanjay
AU - Zhong, Jixin
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Diabetes is an important risk factor for cardiovascular disease. However, clinical data suggests intensive glycemic control significantly increase rather than decrease cardiovascular mortality, which is largely due to the fact that a majority of oral anti-diabetic drugs have adverse cardiovascular effect. There are several large-scale clinical trials evaluating the cardiovascular safety of DPP4 inhibitors, a novel class of oral anti-diabetic medications, which have been recently completed. They were proven to be safe with regard to cardiovascular outcomes. However, concerns on the safety of heart failure have been raised as the SAVOR-TIMI 53 trial reported a 27% increase in the risk for heart failure hospitalization in diabetic patients treated with DPP4 inhibitor saxagliptin. In this review, we will discuss recent advances in the heart failure effects of DPP4 inhibition and GLP-1 agonism.
AB - Diabetes is an important risk factor for cardiovascular disease. However, clinical data suggests intensive glycemic control significantly increase rather than decrease cardiovascular mortality, which is largely due to the fact that a majority of oral anti-diabetic drugs have adverse cardiovascular effect. There are several large-scale clinical trials evaluating the cardiovascular safety of DPP4 inhibitors, a novel class of oral anti-diabetic medications, which have been recently completed. They were proven to be safe with regard to cardiovascular outcomes. However, concerns on the safety of heart failure have been raised as the SAVOR-TIMI 53 trial reported a 27% increase in the risk for heart failure hospitalization in diabetic patients treated with DPP4 inhibitor saxagliptin. In this review, we will discuss recent advances in the heart failure effects of DPP4 inhibition and GLP-1 agonism.
KW - Cardiovascular outcomes
KW - DPP4
KW - Heart failure
KW - Incretin
UR - http://www.scopus.com/inward/record.url?scp=85017517115&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017517115&partnerID=8YFLogxK
U2 - 10.1007/s10741-017-9617-4
DO - 10.1007/s10741-017-9617-4
M3 - Review article
VL - 22
SP - 299
EP - 304
JO - Heart Failure Reviews
JF - Heart Failure Reviews
SN - 1382-4147
IS - 3
ER -